Replimune Group Inc saw its shares rise roughly 40% on Friday after news emerged that the company and the U.S. Food and Drug Administration had come to an agreement on a route to resubmit the company's experimental therapy for advanced melanoma. The information was reported by people familiar with the matter and indicates the company intends to refile its application in the coming days.
At this stage, it remains unspecified whether the forthcoming resubmission will include newly generated clinical data or whether it will rely on additional analyses of the data already collected from the trial program. That detail has not been disclosed by the company or the regulator in the reporting referenced.
The sequence marks a notable turnaround for the program. The drug had previously been rejected in a decision characterized as one of the more contentious regulatory actions during the administration of former FDA Commissioner Marty Makary. According to the reporting, the new agreement with the FDA signals a change in the regulatory posture surrounding the application.
Observers pointed to the timing of the development as notable, saying it illustrates how quickly priorities can shift at the agency following the commissioner's departure earlier this month. The reporting suggests the FDA and Replimune reached common ground on what would be required to move toward another formal review.
For investors and market participants, the immediate effect was pronounced: the company's equity experienced a sharp intraday advance following the disclosure of the reported agreement. Beyond the stock move, the situation leaves open several practical questions for the company and stakeholders, principally what form the resubmission will take and how the regulator will evaluate any new materials submitted.
As the company prepares to file again in the coming days, key details that will determine the regulatory outcome are still unresolved in public reporting. Market participants and observers will be watching for official filings or statements that clarify whether new clinical evidence or analytic reworkings of existing datasets will be part of the resubmission package.